VXRT: Vaxart Inc. Company Value to Net Income

This daily price chart for Vaxart, Inc. (VXRT) with the -1.30 indicator illustrates the business development of creating innovative tablet-based immunity drugs. The company's operations are constrained by strict FDA regulations regarding biohazardous waste disposal. The strategy relies on the development of unique non-injectable forms that provide a pricing advantage, while the model's resilience is based on government support and the protection of intellectual property.

VXRT - Vaxart P/E Multiple over the range 07/04/2022 - 07/12/2025

Analytical breakdowns for Vaxart Corp (VXRT)

- price and consensus price forecast:

Stock Price Vaxart|VXRT - Consensus Target

- market capitalization information:

Market Value Vaxart, Inc.|VXRT - Real Price to Acquire Entire Company

- balance sheet net asset value indicators:

Net Assets per Single Share Vaxart|VXRT - Book Capitalization|Market Capitalization to Book Value vaxart.com|VXRT - Aggregate Company Assets

- debt obligations and liquidity statistics:

- earnings and market ratios statistics:

VXRT - Net Income|Net Profit Forecast Vaxart, Inc.|VXRT - P/E Multiple|Forward P/E Multiple vaxart.com|VXRT - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Vaxart, Inc.|VXRT - Operating profit before deduction of amortization|Earnings per share for the last four quarters Vaxart|VXRT - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months vaxart.com|VXRT - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Vaxart, Inc.

- company sales and revenue statistics:

VXRT - Company Revenue|Company Revenue Forecast Vaxart, Inc.|VXRT - P/S Multiple|Forward Price-to-Revenue Multiple Vaxart, Inc.

Comprehensive company analysis:Vaxart, Inc.

Investors are assessing the resilience of Vaxart, Inc. (VXRT) through the lens of its ability to generate profit. This multiple relates the total market value of the business to net income, determining the payback period for investments. By analyzing the P/E ratio, one can identify whether the asset is overheated or undervalued. For a company investing in a staff of elite oral vaccine developers, this metric reflects the market's faith in future breakthroughs. The fundamental balance here determines the risk of capital freeze.

Competing companies